Thursday, July 27, 2023
CartiHeal has announced the first commercial implantation of Agili-C in the US.
Agili-C is an implant with a bi-phasic design that supports bone remodelling and cartilage regeneration. It was developed to address an unmet need in clinical practise by providing a cost-efficient, off-the-shelf solution for treating knee-joint surface lesions.
The Agili-C scaffold is indicated for the treatment of International Cartilage Repair Society grade III or above knee-joint surface lesion(s) with a total treatable area of 1-7cm2, without severe osteoarthritis (Kellgren-Lawrence grade 0-3).
It received FDA breakthrough designation status in 2020 and had demonstrated clinical superiority to the surgical standard of care (SSOC), such as microfracture and debridement, in a significant cartilage clinical trial with broad inclusion criteria to mimic real-life patients.
CartiHeal is continuing to advance its technology and aims to make Agili-C available to a wide range of surgical facilities not only in the US but also beyond. This signifies the ongoing efforts to improve cartilage repair and regeneration treatments for patients with knee-joint surface lesions.
